On October 13, 2020, the Norwegian Directorate of Health published a preliminary version of the DRG system (ISF) for 2021. Four new DRGs were introduced.

In early October 2020, the first reimbursable health apps were introduced on the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM). These applications can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers.

In late September 2020, the Austrian version of the DRG system (LKF) 2021 model with the relevant supplementary documents was published in Austria. For 2021, the main changes include the addition of sixteen new procedure codes and the introduction of two new procedure codes for billing in the day-case settings, update of cases flat rates, and adjustments of the cases daily component calculation.

New material codes and related conditions of reimbursement for anchoring and fixation implants for soft tissue were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in August 2020.

In late September 2020, the Swedish version of NordDRG for 2021 was issued by the National Board of Health and Welfare (Socialstyrelsen). Four (4) new DRGs were added, and few minor changes in DRG names and logic were made.

On September 24, 2020, NHS England opened a consultation on clinical commissioning policy for the use of catheter ablation for paroxysmal and persistent atrial fibrillation. Comments can be submitted until October 24, 2020.

On September 30, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) published the position that transcatheter aortic valve implantation (TAVI) in patients with aortic stenosis and a high risk of surgery is eligible for reimbursement under basic health insurance package.

New material codes and related conditions of reimbursement for middle ear implants were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in August 2020.

In September 2020, Swedish Medical Technologies Product (MTP) Council decided to evaluate gene diagnostics for breast cancer within the Orderly introduction framework. Swedish Dental and Pharmaceutical Benefits Agency (TLV) will perform health economic assessments of these tests, including MammaPrint, Oncotype DX, ProSigna, and EndoPredict

On August 6, 2020, the Ministry of Solidarity and Health published an Order (of August 4, 2020) listing the rotational atherectomy systems ROTAPRO and ROTALINK PLUS of the company Boston Scientific under Title V of the list of reimbursable products and services provided for in Article L. 165-1 of the Social Security Code (LPPR List).

NHS England announced that the specialized High-Cost Tariff-Excluded Devices (HCTED) program is restarted working with NHS providers and NHS Supply Chain colleagues, throughout July and August 2020.

In September 2020, the list of companion diagnostic tests, which are evaluated for reimbursement, was updated. INAMI has a specific reimbursement framework for companion diagnostic tests. INAMI Nomenclature codes from Article 33ter can only be reimbursed in relation to specific biomarker tests and drugs from Chapter VIII of the reimbursable pharmaceutical specialties (Royal Decree of February 1, 2018).